Most Analysts Rate Boston Scientific a ‘Buy’
Based on the recommendations of 27 brokerage firms in a Bloomberg survey, about 78% gave Boston Scientific a consensus rating of “buy.”
On September 27, 2016, Boston Scientific (BSX) was trading at a forward PE (price-to-earnings) ratio of ~21.5x.
Boston Scientific (BSX) offers a leading portfolio of rhythm management devices around the world.
On September 27, 2016, Boston Scientific (BSX) announced the acquisition of EndoChoice Holdings for $210 million.
Boston Scientific (BSX) is consistently working towards gaining higher market share in the attractive TAVR (transcatheter aortic valve replacement) market in Europe.
On September 26, 2016, Boston Scientific was trading ~51% above its 52-week low of $15.7 on February 8, 2016.
The combined Teva Pharmaceutical–Allergan Generics company filed 65 ANDAs (Abbreviated New Drug Applications) in 2015.
In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.
The acquisition of Allergan’s (AGN) generic business has helped Teva’s R&D pipeline become the strongest generic drug pipeline in the world.
Operating in 26 countries, Teva Pharmaceutical (TEVA) is well positioned to benefit from the opportunity in growth markets.
Teva Pharmaceutical’s (TEVA) strategy of selectively focusing on certain countries has enabled it to see double-digit organic growth in the growth markets.
Despite its large size and large scope of operations, Teva Pharmaceutical’s European generics business has risen in operating profit margins by about 1,000 basis points.
Teva Pharmaceutical (TEVA) currently operates in three types of markets in the European Union.
Teva is in the first three positions in 26 countries in the European Union. The Teva–Allergan Generics deal helped Teva expand.
With a share of about 14%, Teva Pharmaceutical Industries (TEVA) is currently the top-ranking player in the European generic pharmaceutical market.
Because of its drug portfolio, manufacturing operations, and customer relationships, Teva expects to benefit from new trends in the US generic market.
BioMarin’s (BMRN) early-stage pipeline includes BMN-270, a gene therapy program for hemophilia A and vosoritide, which is indicated for achondroplasia.
According to a Bloomberg survey of 19 brokerage companies on September 26, 2016, 94.7% of analysts recommended the stock as a “buy.”
BioMarin Pharmaceutical (BMRN) expects its existing commercialized drugs to add $1.1 billion and $1.2 billion to its top line in 2016.
BioMarin’s application for cerliponase alfa, an enzyme replacement therapy, is under review by the FDA for the treatment of CLN2 disease.